本文已被：浏览 296次 下载 1297次
投稿时间：2022-10-28 网络发布日期：2023-06-20
投稿时间：2022-10-28 网络发布日期：2023-06-20
中文摘要: 目的 探讨血清半乳糖凝集素-3（Galectin-3）、高迁移率族蛋白A2（HMGA2）、神经纤毛蛋白-1（NRP-1）、癌胚抗原（CEA）、鳞癌相关抗原（SCC-Ag）及细胞角蛋白-19片段（CYFRA 21-1）在非小细胞肺癌（NSCLC）患者中的水平变化及临床意义。 方法 回顾性选取2019年3月至2022年3月滁州市第一人民医院诊治或检查的79例NSCLC患者（NSCLC组）、39例良性肺部疾病患者（良性对照组）及50例健康体检者（健康对照组）,比较三组血清Galectin-3、HMGA2、NRP-1、CEA、SCC-Ag及CYFRA 21-1水平的差异,分析Galectin-3、HMGA2、NRP-1和常规肿瘤标志物与NSCLC临床病理特征关系及对淋巴结转移、临床分期预测价值。 结果 NSCLC组血清Galectin-3、HMGA2、NRP-1、CEA、SCC-Ag、CYFRA 21-1表达高于良性对照组、健康对照组（P＜0.05）。血清Galectin-3、HMGA2、NRP-1、CYFRA 21-1、CEA水平与NSCLC患者的肿瘤直径、分化程度、淋巴结转移、临床分期，呈全部或部分相关（P＜0.05），SCC-Ag与病理类型有关（P＜0.05）。多因素logistic回归分析显示,Galectin-3、HMGA2、NRP-1、CEA、CYFRA 21-1是影响NSCLC淋巴结转移、临床分期Ⅲ~Ⅳ期的独立危险因素（P＜0.05）。血清Galectin-3、HMGA2、NRP-1、CEA、CYFRA 21-1预测NSCLC淋巴结转移的AUC分别为0.950、0.878、0.745、0.771和0.706,预测NSCLC临床分期Ⅲ~Ⅳ期的AUC分别为0.934、0.865、0.755、0.695和0.698。 结论 NSCLC患者血清Galectin-3、HMGA2、NRP-1及常规肿瘤标志物CEA、SCC-Ag、CYFRA 21-1水平均明显升高,且Galectin-3、HMGA2、NRP-1均与淋巴结转移、临床分期有关,可作为NSCLC淋巴结转移及临床分期的新型预测指标。
Abstract:Objective To explore the changes and clinical significance of serum levels of Galectin-3, high mobility group protein A2 (HMGA2) , neuropilin-1 (NRP-1) , carcino-embryonic antigen (CEA) , squamous cell carcinoma antigen (SCC-AG) and cytokeratin-19 fragment (CYFRA 21-1) in patients with non-small cell lung cancer (NSCLC) . Methods A retrospective study was conclucted on 79 patients with NSCLC (NSCLC group) , 39 patients with benign lung diseases (benign control group) and 50 healthy examinees (healthy control group) treated or examined in Chuzhou First People's Hospital from March 2019 to March 2022. The serum levels of Galectin-3, HMGA2, NRP-1, CEA, SCC-Ag and CYFRA 21-1 were compared among three groups to analyze the associations of Galectin-3, HMGA2 and NRP-1 with clinicopathological characteristics of NSCLC and their predictive value on lymph node metastasis and clinical staging of NSCLC. Results The serum levels of Galectin-3, HMGA2, NRP-1, CEA, SCC-Ag and CYFRA 21-1 in NSCLC group were significantly higher than those in benign control group and healthy control group (P＜0.05) . The serum levels of Galectin-3, HMGA2, NRP-1, CEA and CYFRA 21-1 were all or partially correlated with tumor diameter, differentiation, lymph node metastasis and clinical stage in NSCLC patients (P<0.05) , and SCC-Ag level was related to pathological type (P<0.05) . Multivariate logistic regression analysis showed that Galectin-3, HMGA2, NRP-1, CEA and CYFRA 21-1 were the independent risk factors influencing lymph node metastasis and clinical stage Ⅲ-Ⅳ of NSCLC (P＜0.05) . The AUCs of serum Galectin-3, HMGA2, NRP-1, CEA and CYFRA 21-1 in predicting lymph node metastasis in NSCLC were 0.950, 0.878, 0.745, 0.771 and 0.706, respectively, and the AUCs in predicting clinical stage Ⅲ-Ⅳ were 0.934, 0.865, 0.755, 0.695 and 0.698, respectively. Conclusion In the patients with NSCLC, the serum levels of Galectin-3, HMGA2, NRP-1, CEA, SCC-Ag and CYFRA 21-1 are significantly increased, and Galectin-3, HMGA2 and NRP-1 are related to lymph node metastasis and clinical staging. They can be used as new predictive indicators of lymph node metastasis and clinical staging of NSCLC.
keywords: Non-small cell lung cancer Galectin-3 High mobility group protein A2 Neuropilin-1 Carcino-embryonic antigen Squamous cell carcinoma antigen Cytokeratin-19 fragment Lymph node metastasis Clinical staging
文章编号： 中图分类号：R734.2 文献标志码：A
基金项目:
引用文本：
王维飞, 何广思, 胡加海.非小细胞肺癌患者六种血清指标的变化及其检测价值[J].中国临床研究,2023,36(6):849-855.
王维飞, 何广思, 胡加海.非小细胞肺癌患者六种血清指标的变化及其检测价值[J].中国临床研究,2023,36(6):849-855.